Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Business
GSK Plans Shift In Business Direction ...
July 28, 2008
| A version of this story appeared in
Volume 86, Issue 30
British drugmaker GlaxoSmithKline has established a new set of priorities aimed at reducing its financial exposure to the small-molecule pharmaceuticals business. Last week, CEO Andrew Witty told investors that the company plans new investments in vaccines, consumer health care, and biopharmaceuticals. GSK also plans to expand its business in emerging economies, and to that end it signed a licensing collaboration with the South African generic drug company Aspen Pharmacare under which it gains access to Aspen's portfolio of more than 450 mostly generic drug molecules.
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on X